A phase II study of mifepristone (RU‐486) in castration‐resistant prostate cancer, with a correlative assessment of androgen‐related hormones

@article{Taplin2008API,
  title={A phase II study of mifepristone (RU‐486) in castration‐resistant prostate cancer, with a correlative assessment of androgen‐related hormones},
  author={Mary-Ellen Taplin and Judith Manola and W. Oh and P. W. Kantoff and G. Bubley and M. Smith and D. Barb and C. Mantzoros and E. Gelmann and S. Balk},
  journal={BJU International},
  year={2008},
  volume={101}
}
  • Mary-Ellen Taplin, Judith Manola, +7 authors S. Balk
  • Published 2008
  • Medicine
  • BJU International
  • To evaluate mifepristone (RU‐486) in patients with castration‐resistant prostate cancer (CRPC), with a correlative assessment of serum androgens and androgen metabolites 
    Persistent androgen receptor addiction in castration-resistant prostate cancer
    • 38
    • Open Access

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 39 REFERENCES